vs
Side-by-side financial comparison of Concord Medical Services Holdings Ltd (CCM) and Bio-Techne (TECH). Click either name above to swap in a different company.
Concord Medical Services Holdings Ltd is an integrated healthcare provider specializing in oncology care, radiotherapy, and medical diagnostic imaging services focused on the Chinese market. It operates a network of cancer treatment centers, partners with public and private medical institutions to deliver care, and offers medical equipment management solutions.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $295.9M | ||
| Q2 25 | — | $317.0M | ||
| Q1 25 | — | $316.2M | ||
| Q4 24 | — | $297.0M | ||
| Q3 24 | — | $289.5M | ||
| Q2 24 | — | $306.1M | ||
| Q1 24 | — | $303.4M | ||
| Q4 23 | — | $272.6M |
| Q4 25 | — | $38.0M | ||
| Q2 25 | — | $-17.7M | ||
| Q1 25 | — | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | — | $33.6M | ||
| Q2 24 | — | $40.6M | ||
| Q1 24 | — | $49.1M | ||
| Q4 23 | — | $27.5M |
| Q4 25 | — | 64.6% | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% | ||
| Q4 23 | — | 64.8% |
| Q4 25 | — | 18.4% | ||
| Q2 25 | — | -7.5% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | — | 16.0% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | — | 15.0% | ||
| Q1 24 | — | 22.1% | ||
| Q4 23 | — | 13.9% |
| Q4 25 | — | 12.8% | ||
| Q2 25 | — | -5.6% | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | — | 11.6% | ||
| Q2 24 | — | 13.3% | ||
| Q1 24 | — | 16.2% | ||
| Q4 23 | — | 10.1% |
| Q4 25 | — | $0.24 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.14 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | — | $0.21 | ||
| Q2 24 | — | $0.26 | ||
| Q1 24 | — | $0.31 | ||
| Q4 23 | — | $0.17 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
